Clinical Trials in North Carolina

Showing 17281-17300 of 20,428 trials

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

NCT00024570

IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell lines indicating that it may show a therapeutic benefit. In reciprocal competition experiments, the interaction between IL13-PE38QQR and the IL13 receptors was shown to be highly specific for human glioma cells. IL13-PE38QQR will be infused in two courses of 96 hours each, eight weeks apart, directly into the malignant brain tumors of patients to determine the dose of drug these patients can tolerate. After that, the selected dose will be studied to give an estimate of the response rate, response duration, time to response, and survival after infusing that dose of IL13-PE38QQR into the recurrent malignant glioma.

Malignant GliomaGlioblastoma MultiformeAnaplastic Astrocytoma+1 more

INSYS Therapeutics Inc60 participantsStarted Nov 2000

Birmingham, Alabama, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +5 more locations

COMPLETED41 miles

Registry of AngioJet Use in the Peripheral Vascular System

NCT01086215

The Registry involves the collection of information for research and educational purposes only on the use of AngioJet in the peripheral vascular system.

Peripheral Vascular DiseaseEmbolism and ThrombosisVenous Thrombosis

Boston Scientific Corporation500 participantsStarted Jan 2010

Glendale, Arizona, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +33 more locations

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

Registry of AngioJet Use in the Peripheral Vascular System

Find Trials by Condition in North Carolina

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough

Maraviroc in Rheumatoid Arthritis

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

An Exploratory Genetic Study in Participants With Psoriasis

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

Responsive Feeding Study

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer